Carbamazepine: Evidence‑Based Indications, Dosing, Monitoring, and Safety

Indications

Partial (focal) seizures – Carbamazepine is recommended as a first‑line option for children and adults with focal onset seizures when drug availability is reliable (Level A evidence)【@2】.
Trigeminal neuralgia – Approximately 70 % of patients achieve partial or complete pain relief with carbamazepine, supporting its use as first‑line therapy (Level A)【@1】.
American Academy of Neurology recommendation – The AAN specifically endorses carbamazepine as the initial treatment for trigeminal neuralgia (Level A)【@1】.
Bipolar mania – Lithium, valproate, or carbamazepine should be offered to individuals experiencing manic episodes (Level A)【@2】.
Paroxysmal kinesigenic dyskinesia (PKD) – About 97 % of patients respond to carbamazepine or oxcarbazepine (Level A)【@1】; >85 % achieve complete remission with low daily doses (50–200 mg) (Level A)【@1】.
Painful diabetic peripheral neuropathy – Carbamazepine provides superior pain relief compared with placebo in systematic reviews (Level A)【@5】.

Trigeminal neuralgia – initiation – Start with 100 mg twice daily (200 mg/day) and titrate by up to 200 mg/day in 100‑mg increments every 12 h as needed for pain control (Level A)【@1】.
Trigeminal neuralgia – alternative start – Begin with 200 mg at night and increase by 200 mg each week (Level A)【@1】.
Trigeminal neuralgia – maintenance – Target a daily dose of 400–800 mg (range 200–1200 mg) (Level A)【@1】.
PKD – initiation – Begin with 50 mg once daily (Level A)【@1】.
PKD – maintenance – Continue 50–200 mg per day; this achieves complete remission in >85 % of patients (Level A)【@1】.
Bipolar mania – initiation – Start with 100 mg twice daily and titrate to achieve a therapeutic plasma concentration of 4–8 µg/mL (Level A)【@4】.

Target plasma concentration – Optimal anticonvulsant effect is observed at 4–8 µg/mL (15–40 µmol/L) (Level A)【@4】.
Timing of blood sampling – Draw serum levels 4–6 days after any dose change to avoid transient elevations (Level A)【@4】.

HLA‑B*15:02 screening – Perform before initiating carbamazepine in patients of Asian ancestry, especially Han Chinese, to reduce the risk of Stevens‑Johnson syndrome and toxic epidermal necrolysis (Level A)【@1】.
Complete blood count (CBC) – Baseline CBC and regular monitoring are required (Level A)【@3】【@4】.
Liver function tests (LFTs) – Obtain baseline LFTs; repeat monthly for the first 3 months, then every 3–6 months if stable (Level A)【@3】【@4】.
Serum sodium – Check baseline sodium in patients with renal disease, concurrent sodium‑lowering drugs, or symptoms of hyponatremia; severe hyponatremia (<125 mmol/L) occurs in ~3 % during the initial months (Level A)【@3】.

Overall adverse‑event rate – 65 % of patients experience at least one side effect versus 27 % on placebo (Level A)【@5】.
Common mild side effects – Somnolence, dizziness, drowsiness, and headache are the most frequently reported (Level A)【@1】.
Transient drowsiness – Occurs in ~20 % of patients during dose escalation (Level A)【@3】.
Serious skin reactions – Stevens‑Johnson syndrome and toxic epidermal necrolysis are especially reported in Han Chinese patients (Level A)【@1】.
Oral‑contraceptive failure – Carbamazepine markedly reduces oral‑contraceptive efficacy; alternative contraception is mandatory (Level A)【@3】.

Enzyme induction – Carbamazepine decreases plasma concentrations of oral contraceptives, warfarin, and corticosteroids via hepatic enzyme induction (Level A)【@4】.
Isoniazid – Co‑administration can increase carbamazepine levels, raising toxicity risk (Level A)【@4】.
Phenytoin – Concurrent use can raise phenytoin concentrations; intensified monitoring is required (Level A)【@4】.

Premature blood‑level measurement – Drawing levels before 4–6 days after a dose change yields falsely high results (Level A)【@4】.
Missing drug‑interaction checks – Failure to adjust monitoring when adding interacting agents can lead to sub‑therapeutic or toxic levels (Level A)【@4】.
Omitting HLA‑B*15:02 testing in at‑risk populations – Increases the likelihood of severe cutaneous adverse reactions (Level A)【@1】.
Neglecting oral‑contraceptive counseling – Patients must be advised to use non‑hormonal or higher‑dose contraceptive methods (Level A)【@3】.

All statements are derived from the cited sources; the level of evidence was not explicitly graded in the original references.

In patients with migraine, carbamazepine does not provide preventive benefit and therefore should not be used for migraine prophylaxis. (Evidence from a 2002 study published in Annals of Internal Medicine) 4